Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancer.

PURPOSE: To develop a risk score based on a prognostic model and a nomogram integrating baseline clinicopathological variables to predict bladder cancer-specific survival (BCSS) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) patients. METHODS: We retrospectively identified a consecutive sample of 247 MIBC patients treated with cisplatin-based NAC-plus-cystectomy in two Spanish hospitals between 2000 and 2019. Age at MIBC diagnosis, sex, histology, lymphovascular invasion, previous non-MIBC, hydronephrosis, and clinical TNM were included in the initial Cox regression model. A risk score was computed based on the final prognostic model and a nomogram was used to estimate BCSS at 2 and 5 years. RESULTS: Median age was 66 years; 89% were males; 83% had pure urothelial carcinoma; 16.2% had previous non-MIBC. Clinical stage was T2N0, T3-4aN0, and Tx-4N + in 24%, 57%, and 19% of patients, respectively. Complete pathological response was seen in 29.4% and downstaging to non-MIBC (ypT1, ypTa, ypTis) in 12.5% of patients. Overall 5-year BCSS was 59%. Four prognostic factors were identified: variant histology, previous non-MIBC, female sex and hydronephrosis. By adding the points attributed to each of these factors, we categorized patients in three groups: low-risk (0 points); intermediate-risk (1-9 points); high-risk (≥ 10 points). Five-year BCSS was 72%, 53%, and 15%, respectively (p < 0.0001). CONCLUSION: We developed a nomogram and risk score based on four baseline clinicopathological characteristics to predict BCSS to NAC-plus-cystectomy in MIBC patients. If validated in prospective studies, this nomogram can be useful for selecting patients likely to benefit from NAC.

[Can a single value of a perypheric inflammatory response marker predict the response to BCG?] / Ratios neutrófilo/linfocito y plaqueta/linfocito: ¿Se asocian con la respuesta al tratamiento con BCG en tumores vesicales no músculoinvasivos de alto grado?

OBJECTIVES: To evaluate the association of neuthophyl/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) with BCG intravesical responses in patients with initial diagnosis of non/muscle invasive bladder tumor high-risk (NMIBC). MATERIAL AND METHODS: Retrospective multicenter study on patients with initial diagnosis of high-grade NMIBC treated with BCG between January 2016 and December 2017. Initially a total of 74 patients were collected. Those patients with mixt pathology, cis, chronic corticoid usage and lost to follow-up, were excluded. Induction BCG (x6) and BCG maintenance schedules were administered (x9) over 1 year. Demographic variables (sex, age, BMI) and blood variables (NLR, PLR) before BCG instillation were collected. Response to treatment was defined as absence of recurrence and/ or progression. A statistical analysis with T-student, Chi square, ANOVA and ROC curves was performed. RESULTS: Final study cohort included a total of 50 patients. 10 females and 40 males. Median age was 70 year old. All patients had pure urothelial carcinoma, 12 with pTa and 38 with pT1. Median follow-up was 24 months. A total of 28% had a recurrence. No correlation between NLR or PLR and BCG response was observed (p=0.738; p= 0.768). Neither a cut off was established through ROC curves. At multivariate analysis, there was no significative relationship between recurrence and the clinical and blood samples analyzed (sec, age, BMI, NLR, PLR)CONCLUSION: No correlation between NLR and PLR has been reported with BCG response on high-grade NMIBC.

OBJETIVOS: Evaluar la asociación de la ratio neutrófilo/linfocito (RNL) y ratio plaqueta/linfocito (RPL) con la respuesta al tratamiento mediante instilaciones de Bacilo Calmette Guerin (BCG) intravesical, en pacientes con diagnóstico inicial de tumor vesical no músculo-invasivos (TVNMI) de alto riesgo.MATERIAL Y MÉTODOS: Estudio retrospectivo multicéntrico con pacientes diagnosticados de tumor vesical inicial de alto riesgo y sometidos a instilaciones endovesicales con BCG entre enero 2016 y diciembre 2017. Inicialmente se recogieron 74 pacientes con tumor vesical inicial. Se excluyeron aquellos sin estirpe urotelial pura, con carcinoma in situ (Cis) asociado, con tratamientos corticoideos crónicos y perdidos durante el seguimiento. Instilamos dosis completa de BCG (81mg) con pauta de inducción (6 dosis) y mantenimiento (9 dosis) durante un año. Se recogieron variables demográficas (sexo, edad e índice de masa corporal) y analíticas (RNL y RPL) previas al inicio del tratamiento con BCG. Definimos respuesta al tratamiento como ausencia de recidiva y/o progresión. Se realizó análisis estadístico mediante t de student, Chi cuadrado, ANOVA y curvas ROC. RESULTADOS: La cohorte del estudio incluyó finalmente 50 pacientes: 10 mujeres y 40 varones, con una edad media de 70 años. Todos estos pacientes tenían tumor urotelial puro alto grado, 12 de ellos estadio Ta y 38 estadio T1. El seguimiento mínimo fue de 24 meses, presentando recidiva tumoral un 28% de los pacientes. No se encontró relación entre RNL y éxito de la BCG (p=0,738) ni entre RPL y éxito de BCG (p=0,768). Tampoco pudimos establecer un punto de corte mediante curvas ROC. En el análisis multivariante, no encontramos significación estadística entre la recidiva tumoral y los datos analizados (Variables demográficas: Edad, sexo, índice de masa corporal y variables analíticas: RNL/RPL).CONCLUSIÓN: Pese a lo descrito en la literatura, no hemos encontrado asociación entre la RNL ni la RPL con la respuesta al tratamiento con BCG en TVNMI de alto riesgo.

Ratios neutrófilo/linfocito y plaqueta/linfocito: ¿se asocian con la respuesta al tratamiento con bcg en tumores vesicales no músculoinvasivos de alto grado? / Neutrophil/lymphocyte and platelet/lymphocyte ratios: are they associated with response to bcg treatment in high-grade non-muscle-invasive bladder tumors?

Objetivos: Evaluar la asociación de laratio neutrófilo/linfocito (RNL) y ratio plaqueta/linfocito(RPL) con la respuesta al tratamiento mediante instilaciones de Bacilo Calmette Guerin (BCG) intravesical, enpacientes con diagnóstico inicial de tumor vesical nomúsculo-invasivos (TVNMI) de alto riesgo.Material y métodos: Estudio retrospectivo multicéntrico con pacientes diagnosticados de tumor vesicalinicial de alto riesgo y sometidos a instilaciones endovesicales con BCG entre enero 2016 y diciembre2017. Inicialmente se recogieron 74 pacientes contumor vesical inicial. Se excluyeron aquellos sin estirpeurotelial pura, con carcinoma in situ (Cis) asociado, con tratamientos corticoideos crónicos y perdidos durante elseguimiento. Instilamos dosis completa de BCG (81mg)con pauta de inducción (6 dosis) y mantenimiento (9 dosis) durante un año. Se recogieron variables demográficas (sexo, edad e índice de masa corporal) y analíticas(RNL y RPL) previas al inicio del tratamiento con BCG.Definimos respuesta al tratamiento como ausencia derecidiva y/o progresión. Se realizó análisis estadísticomediante t de student, Chi cuadrado, ANOVA y curvasROC.Resultados: La cohorte del estudio incluyó finalmente50 pacientes: 10 mujeres y 40 varones, con una edadmedia de 70 años. Todos estos pacientes tenían tumorurotelial puro alto grado, 12 de ellos estadio Ta y 38estadio T1. El seguimiento mínimo fue de 24 meses,presentando recidiva tumoral un 28% de los pacientes.No se encontró relación entre RNL y éxito de la BCG(p=0,738) ni entre RPL y éxito de BCG (p=0,768). Tampoco pudimos establecer un punto de corte mediantecurvas ROC.En el análisis multivariante, no encontramos significación estadística entre la recidiva tumoral y los datos analizados (Variables demográficas: Edad, sexo, índice demasa corporal y variables analíticas: RNL/RPL).Conclusion: Pese a lo descrito en la literatura, nohemos encontrado asociación entre la RNL ni la RPL con...(AU)

Objetives: To evaluate the associationof neuthophyl/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) with BCG intravesical responses inpatients with initial diagnosis of non/muscle invasivebladder tumor high-risk (NMIBC).Materials and methods: Retrospective multicenterstudy on patients with initial diagnosis of high-gradeNMIBC treated with BCG between January 2016 andDecember 2017. Initially a total of 74 patients werecollected. Those patients with mixt pathology, cis, chronic corticoid usage and lost to follow-up, were excluded.Induction BCG (x6) and BCG maintenance scheduleswere administered (x9) over 1 year. Demographic variables (sex, age, BMI) and blood variables (NLR, PLR)before BCG instillation were collected. Response totreatment was defined as absence of recurrence and/or progression. A statistical analysis with T-student, Chisquare, ANOVA and ROC curves was performed.Results: Final study cohort included a total of 50 patients. 10 females and 40 males. Median age was 70year old. All patients had pure urothelial carcinoma, 12with pTa and 38 with pT1. Median follow-up was 24months. A total of 28% had a recurrence. No correlationbetween NLR or PLR and BCG response was observed(p=0.738; p= 0.768). Neither a cut off was established through ROC curves.At multivariate analysis, there was no significative relationship between recurrence and the clinical and bloodsamples analyzed (sec, age, BMI, NLR, PLR)Conclusion: No correlation between NLR and PLRhas been reported with BCG response on high-gradeNMIBC.(AU)

[The management of medical waste]. / Gestión de residuos sanitarios. Despertar a la ecología.

Sanitary residues fall inside the general category of residues produced; therefore, we must begin with general aspects such as the habit of producing residues, the awareness a country has regarding this problem and the treatment policy to apply in order to deal with these residues. The author also established the characteristics and the classification for these residues as well as the way identify the diverse types of residues for each specific area they come from.

[Medical waste management]. / Tratamiento de residuos sanitarios. Despertar a la ecología.

The author describes the treatment systems which should be applied, particularly when dealing with groups III and IV as explained in the previous article, in order to counteract their noxious effects on persons and the environment. Some treatment systems are compared and the author explains how to treat radioactive wastes, residues and sterilization, microwaves and the incineration of sanitary residues.

Tratamiento de residuos sanitarios / Treatment of sanitary residues

Se describen los sistemas de tratamiento que deben aplicarse, en particular a los grupos III y IV (explicados en el artículo anterior), para contrarrestar sus efectos nocivos sobre las personas y el medio. Se comparan algunos sistemas de tratamiento, y se explica el tratamiento de los residuos radioactivos, residuos y esterilización, microondas y la incineración de los residuos sanitarios (AU)

Curso de cerámica

Contenido: 1. Introducción al comportamiento de las pastas cerámicas. 2. La fabricación de los materiales cerámicos: trituración, conformado y secado. 3. La fabricación de los materiales cerámicos: cocción, combustión y quemadores.